Research Topics
Species | C M BollardSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Gene-marking studies of hematopoietic cellsC M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Int J Hematol 73:14-22. 2001..With continuing advances in gene-marking technology, the value of the information provided by these studies increases, thereby ensuring their continued relevance to the field of gene transfer...
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
Blood 110:2838-45. 2007..This study is registered at http://www.cancer.gov/clinicaltrials (protocol IDs: BCM-H-9936, NCT00062868, NCT00070226)...- Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphomaCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, 77030, USA
Clin Lymphoma Myeloma 6:342-7. 2006 - The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin diseaseCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
J Immunother 27:317-27. 2004..This approach is being used in a current clinical trial... - In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantationCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Leuk Lymphoma 47:837-42. 2006.... - Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's diseaseCatherine M Bollard
Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
J Exp Med 200:1623-33. 2004..One additional patient had a partial response, and five had stable disease. The performance and fate of these human tumor antigen-specific T cells in vivo suggests that they might be of value for the treatment of EBV+ Hodgkin lymphoma... - Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantationG D Myers
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
Bone Marrow Transplant 39:677-86. 2007..In conclusion, recipients of alternative donor transplants at our institution have significantly delayed adv-specific cellular immune recovery, which correlates to an increased risk of adv-associated morbidity and mortality... - T cell therapiesS Gottschalk
Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3-3320, 77030 Houston, USA
Ernst Schering Found Symp Proc 4:69-82. 2006..Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens... - Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)G D Myers
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children's Hospital, Houston, 77030, USA
Bone Marrow Transplant 36:1001-8. 2005..This work will help in identifying at-risk populations for our upcoming immunotherapy trial using adoptively transferred donor-derived adenovirus-specific cytotoxic T lymphocytes... 
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabineNabil Ahmed
Center for Cell and Gene Therapy, Texas Children s Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 14:1298-304. 2008..Thus, the regimen that we describe can be used with minimal toxicity to effectively overcome graft failure after myeloablative HSCT in children...- T-cell immunotherapy for adenoviral infections of stem-cell transplant recipientsA M Leen
Center for Cell and Gene Therapy, Department of Pediatrics-Hem/Onc, Baylor College of Medicine, 6621 Fannin St, MC3-3320 Houston, TX 77030, USA
Ann N Y Acad Sci 1062:104-15. 2005..Thus, we have characterized human T-cell responses to adenovirus in vitro and explored the potential of adoptive T-cell immunotherapy as a prophylactic or therapeutic strategy for adenovirus infections posttransplant... - Gene therapy for paediatric leukaemiaR F Rousseau
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
Expert Opin Biol Ther 1:663-74. 2001..With the continued scientific advancements in this field, gene therapy will almost certainly have a major impact on the treatment of paediatric leukaemia in the future... - Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphomaKarin C Straathof
Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children's Hospital, Houston, TX 77030, USA
J Immunol 175:4137-47. 2005..These new LMP2 epitopes broaden the diversity of HLA alleles with available epitopes, and, in particular, those epitopes conserved between EBV strains provide valuable tools for immunotherapy and immune monitoring... - Options for T-cell based therapiesH E Heslop
Center for Gene and Cell Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA
Vox Sang 87:230-4. 2004 - T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?A A Kennedy-Nasser
Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin Street, Houston, TX 77030, USA
Bone Marrow Transplant 40:93-104. 2007..This review focuses on the T-cell strategies currently available to allay disease while minimizing toxicities in patients who have undergone HSCT... - Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institutionJ A Shafer
Center for Cell and Gene Therapy, Houston, TX 77030, USA
Leuk Lymphoma 51:664-70. 2010..Our data show encouraging outcomes for patients with chemosensitive relapsed HL who receive hematopoietic stem cell transplant (HSCT) and support the value of the procedure even when the disease is chemoresistant... - Immune therapy for EBV infections after hemopoietic stem-cell transplantH E Heslop
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston TX 77030, USA
Cytotherapy 4:433-4. 2002 - Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipientsHelen E Heslop
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Blood 115:925-35. 2010.... - Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patientsChrystal U Louis
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Blood 113:2442-50. 2009..Lymphodepleting mAbs prior CTL transfer may represent an alternative to chemotherapy to enhance expansion of infused CTL. This study is registered at (http://www.clinialtrials.gov) as NCT00608257... - Immunotherapy targeting EBV-expressing lymphoproliferative diseasesCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
Best Pract Res Clin Haematol 21:405-20. 2008..A number of strategies to genetically modify the infused T cells and modulate the host environment are under evaluation... - Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantationKenneth P Micklethwaite
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX, USA
Blood 115:2695-703. 2010..This approach may prove beneficial for patients with high-risk B-ALL who have recently received an HSC or CB transplant and are at risk of infection and relapse... - Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12Aaron E Foster
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, 6621 Fannin Street, Houston, TX 77030, USA
J Immunother 30:506-16. 2007..Thus, T cells provide a platform for the generation of autologous APC that can be customized to express both antigens and therapeutic molecules for the induction of antigen-specific T cell immunity... - Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopesPatrick J Hanley
Department of Immunology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Center for Cell and Gene Therapy, Houston, TX 77030, USA
Blood 114:1958-67. 2009..This study is registered at www.clinicaltrials.gov as NCT00078533... - Immunotherapy for Epstein-Barr virus-associated cancers in childrenKarin C M Straathof
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Oncologist 8:83-98. 2003..If these strategies to improve the therapeutic potential of immunotherapy for EBV-associated tumors prove successful, this type of treatment may be adapted to other tumors expressing known (viral) antigens... - Adoptive immunotherapy for posttransplantation viral infectionsCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
Biol Blood Marrow Transplant 10:143-55. 2004..The use of genetically modified T cells or the use of newer suicide genes may result in improved safety and efficacy... - Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytesKarin C M Straathof
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, 1102 Bates St, Suite 1120, Houston, TX 77030, USA
Blood 105:1898-904. 2005..These results demonstrate that administration of EBV-specific CTLs to patients with advanced NPC is feasible, appears to be safe, and can be associated with significant antitumor activity... - Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with AlemtuzumabR Lamba
Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
Bone Marrow Transplant 36:797-802. 2005..However, in the majority of patients, infection is transient, and antiviral T cell reconstitution is rapid. Monitoring with CMV-specific CTLs may help identify the subset of patients at risk from recurrent infection or disease... - Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantationAnn M Leen
Center for Cell and Gene Therapy and Departments of Pediatrics, Immunology, Medicine, and Virology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Houston, TX 77030, USA
Blood 114:4283-92. 2009..This trial was registered at www.clinicaltrials.gov as #NCT00590083... - Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimenAlana A Kennedy-Nasser
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 14:1245-52. 2008..For children undergoing stem cell transplantation (SCT) from alternative donors, alemtuzumab with a myeloablative conditioning regimen resulted in DFS comparable to MSD... - Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapyAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin Street, MC 3 3320, Houston, TX 77030, USA
J Virol 82:546-54. 2008.... - A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cellsHans-Joachim Wagner
Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Gene Ther 11:81-91. 2004..Tumor-specific, Flexi-IL12-transduced EBV-specific CTL should have a functional advantage over unmodified CTL, particularly in the presence of the adverse Th2 cytokine environment produced by Hodgkin tumor cells... - Adoptive immunotherapy for Hodgkin's lymphomaAlana A Kennedy-Nasser
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA
Int J Hematol 83:385-90. 2006..In this article, we discuss the promise of Epstein-Barr virus-specific cytotoxic T-lymphocytes, the roles of cytokines, and other strategies for overcoming the immune-evasion mechanisms in Hodgkin's lymphoma... - Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphomaJessica A Shafer
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Cancer Center, Houston, TX 77030, USA
Leuk Lymphoma 51:870-80. 2010..This study suggests that chemoresistant HL SP cells can be targeted by the immune system, providing a rationale for combined chemotherapy and immunotherapy for the treatment of HL... - Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapyClaudia Rossig
Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin Street, Houston, TX 77030, USA
Blood 99:2009-16. 2002..They efficiently lyse both. EBV-specific T cells expressing chimeric antitumor receptors may represent a new source of effector cells that would persist and function long-term after their transfer to cancer patients... - Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemiaAlana A Kennedy-Nasser
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 12:1277-84. 2006..We conclude that, for children with SAA, AD transplantation is as effective as MSD transplantation. Further, compared with ATG, preparatory regimens containing Campath may be associated with a lower incidence of extensive, chronic GHVD... - Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genesC Rossig
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Int J Cancer 94:228-36. 2001.... - Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptorKristine Lacuesta
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA
J Immunother (1997) 29:250-60. 2006..They may be of value for treating human cancers, which use TGFbeta as a powerful immune evasion mechanism... - Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individualsAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA
Nat Med 12:1160-6. 2006..Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host... - Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunityCatherine M Bollard
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
Blood 99:3179-87. 2002..Tumor-specific CTLs expressing HATGF-betaRII-Deltacyt should have a selective functional and survival advantage over unmodified CTLs in the presence of TGF-beta-secreting tumors and may be of value in treatment of these diseases... - Adenoviral infections in hematopoietic stem cell transplantationAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 12:243-51. 2006..We discuss the advantages and limitations of T-cell therapy for the prophylaxis and treatment of adenovirus infection posttransplantation... - Pediatric Hodgkin lymphoma: are we over-scanning our patients?N Rathore
Texas Children s Cancer Center and Department of Pediatrics, Baylor College of Medicine, Texas Children s Hospital, Houston, Texas 77030, USA
Pediatr Hematol Oncol 29:415-23. 2012.... - Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative diseaseCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Acta Haematol 110:139-48. 2003..The infusion of EBV-CTL has been demonstrated to be safe and effective in allogeneic HSCT recipients and their use post-SOT is being evaluated... - Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptorAaron E Foster
Center for Cell and Gene Therapy, The Methodist Hospital and Texas Children s Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
J Immunother 31:500-5. 2008..TGF-beta-resistant CTL had a functional advantage over unmodified CTL in the presence of TGF-beta-secreting EBV-positive lymphoma, and had enhanced antitumor activity, supporting the potential value of this countermeasure... - Adoptive T-cell transfer in cancer immunotherapySiok-Keen Tey
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, 77030, USA
Immunol Cell Biol 84:281-9. 2006.... - Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cellsDavid Steiner
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Stem Cells 27:1932-40. 2009..The results suggest that multipotent stem cells can be expanded ex vivo and can contribute meaningfully to long-term hematopoietic engraftment... - Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imagingXin Gao
The Center for Bioengineering and Informatics, The Methodist Hospital and The Methodist Hospital Research Institute, Weill Medical College of Cornell University, Houston, TX 77030, USA
Acad Radiol 17:479-88. 2010..This study develops and validates a Longitudinal Image Navigation and Analysis (LINA) system for this quantitative imaging application... - Genetically engineered T-cells for adoptive immunotherapyMartin Pule
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Curr Opin Mol Ther 4:467-75. 2002..New strategies to target T-cells to tumors and to genetically modify them to make them resistant to tumor evasion mechanisms are being evaluated in preclinical models... - Deficient T(H)-1 responses from TNF-alpha-matured and alpha-CD40-matured dendritic cellsWilliam K Decker
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
J Immunother 31:157-65. 2008..Empirically, the data suggest that DCs matured with these agents are deficient in the induction of type 1 T-helper responses. We further speculate that DCs matured by these methods might be suboptimal for the priming of naive responses...